about
Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in JapanAnalysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?Analysis of new drugs whose clinical development and regulatory approval were hampered during their introduction in Japan.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Delays in psychiatric drug development in Japan.
@en
Delays in psychiatric drug development in Japan.
@nl
type
label
Delays in psychiatric drug development in Japan.
@en
Delays in psychiatric drug development in Japan.
@nl
prefLabel
Delays in psychiatric drug development in Japan.
@en
Delays in psychiatric drug development in Japan.
@nl
P2860
P1476
Delays in psychiatric drug development in Japan
@en
P2093
P2860
P304
P356
10.1111/J.1365-2710.2011.01311.X
P577
2011-10-23T00:00:00Z